XML 20 R10.htm IDEA: XBRL DOCUMENT
v3.25.3

Inventories | 9 Months Ended
--- | ---
Sep. 30, 2025
Inventory Disclosure [Abstract] |
INVENTORIES | INVENTORIES The Company works closely with third parties to manufacture and package finished goods for sale. Based on the arrangements with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival at the Company’s warehouses. The Company then holds such goods in inventory until distribution and sale. These finished goods inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method. The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving goods by comparing sales history and projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value. At September 30, 2025 and December 31, 2024, there were no cumulative net realizable value charges for potential obsolescence and discontinuance losses necessary. The Company purchases the active pharmaceutical ingredient ("API") for Kristalose and Sancuso and maintains the inventory of that raw material. API for the Company's Vaprisol and Vibativ brands were included in the assets associated with the acquisition of those brands and are also included in the raw materials inventory. As these APIs are consumed in the manufacture of our products, the value of the API involved is transferred from raw materials to finished goods. Consigned inventory represents Authorized Generic inventory stored with our partner until shipment to their customers. At September 30, 2025 and December 31, 2024, the Company's net inventories consisted of the following:
|  | September 30, 2025 |  | December 31, 2024
Raw materials and work in process |  | $ | 9,747,221 |  |  | $ | 11,982,045 |
Consigned inventory |  | 51,288 |  |  | 126,090 |
Finished goods |  | 2,320,076 |  |  | 2,897,359 |
Total inventories |  | 12,118,585 |  |  | 15,005,494 |
less non-current inventories |  | (9,183,862) |  |  | (11,005,499) |
Total inventories classified as current |  | $ | 2,934,723 |  |  | $ | 3,999,995 |
At September 30, 2025 and December 31, 2024, the Company's non-current inventories consisted of the following:
| September 30, 2025 |  | December 31, 2024
Vibativ Raw Materials | $ | 4,714,922 |  |  | $ | 6,180,347 |
Kristalose Raw Materials | 2,362,712 |  |  | 2,672,720 |
Vaprisol Raw Materials | 1,173,070 |  |  | 1,172,849 |
Sancuso Raw Materials | 285,153 |  |  | 458,684 |
Caldolor Raw Materials | 16,982 |  |  | — |
Acetadote Raw Materials | 42,718 |  |  | 23,915 |
Ifetroban Raw Materials | 65,270 |  |  | 166,923 |
Kristalose Finished Goods | 177,715 |  |  | — |
Vibativ Finished Goods | 157,477 |  |  | 183,057 |
Caldolor Finished Goods | 118,221 |  |  | 77,382 |
Omeclamox-Pak Raw Materials | 69,622 |  |  | 69,622 |
Total inventories classified as non-current | $ | 9,183,862 |  |  | $ | 11,005,499 |

X
- References No definition available. + Details
Name: | us-gaap_InventoryDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContent + Details
Name: | us-gaap_InventoryDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration